Literature DB >> 15383478

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

William H Geerts1, Graham F Pineo, John A Heit, David Bergqvist, Michael R Lassen, Clifford W Colwell, Joel G Ray.   

Abstract

This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key recommendations in this chapter are the following. We recommend against the use of aspirin alone as thromboprophylaxis for any patient group (Grade 1A). For moderate-risk general surgery patients, we recommend prophylaxis with low-dose unfractionated heparin (LDUH) (5,000 U bid) or low-molecular-weight heparin (LMWH) [< or = 3,400 U once daily] (both Grade 1A). For higher risk general surgery patients, we recommend thromboprophylaxis with LDUH (5,000 U tid) or LMWH (> 3,400 U daily) [both Grade 1A]. For high-risk general surgery patients with multiple risk factors, we recommend combining pharmacologic methods (LDUH three times daily or LMWH, > 3,400 U daily) with the use of graduated compression stockings and/or intermittent pneumatic compression devices (Grade 1C+). We recommend that thromboprophylaxis be used in all patients undergoing major gynecologic surgery (Grade 1A) or major, open urologic procedures, and we recommend prophylaxis with LDUH two times or three times daily (Grade 1A). For patients undergoing elective total hip or knee arthroplasty, we recommend one of the following three anticoagulant agents: LMWH, fondaparinux, or adjusted-dose vitamin K antagonist (VKA) [international normalized ratio (INR) target, 2.5; range, 2.0 to 3.0] (all Grade 1A). For patients undergoing hip fracture surgery (HFS), we recommend the routine use of fondaparinux (Grade 1A), LMWH (Grade 1C+), VKA (target INR, 2.5; range, 2.0 to 3.0) [Grade 2B], or LDUH (Grade 1B). We recommend that patients undergoing hip or knee arthroplasty, or HFS receive thromboprophylaxis for at least 10 days (Grade 1A). We recommend that all trauma patients with at least one risk factor for VTE receive thromboprophylaxis (Grade 1A). In acutely ill medical patients who have been admitted to the hospital with congestive heart failure or severe respiratory disease, or who are confined to bed and have one or more additional risk factors, we recommend prophylaxis with LDUH (Grade 1A) or LMWH (Grade 1A). We recommend, on admission to the intensive care unit, all patients be assessed for their risk of VTE. Accordingly, most patients should receive thromboprophylaxis (Grade 1A).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383478     DOI: 10.1378/chest.126.3_suppl.338S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  459 in total

1.  Detection and Prevention of Post-Operative Deep Vein Thrombosis [DVT] Using Nadroparin Among Patients Undergoing Major Abdominal Operations in India; a Randomised Controlled Trial.

Authors:  Anandan Murugesan; Dina N Srivastava; Uma K Ballehaninna; Sunil Chumber; Anita Dhar; Mahesh C Misra; Rajinder Parshad; V Seenu; Anurag Srivastava; Narmada P Gupta
Journal:  Indian J Surg       Date:  2010-11-16       Impact factor: 0.656

2.  Prolonged use of thromboprophylaxis may not be necessary in laparoscopic colorectal surgery.

Authors:  Paulus Menno Verheijen; Andrew R L Stevenson; Russel W Stitz; David A Clark; Andrew J Clark; John W Lumley
Journal:  Int J Colorectal Dis       Date:  2011-01-27       Impact factor: 2.571

Review 3.  Anticoagulation and psychotropic medications.

Authors:  Maurice Bachawati
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

4.  Preoperative evaluation and risk management.

Authors:  David P Parsons
Journal:  Clin Colon Rectal Surg       Date:  2009-02

5.  Impact of a student-supported pharmacy assessment program on venous thromboembolism prophylaxis rates in hospitalized patients.

Authors:  Laura E Butkievich; Zachary A Stacy; Michael W Daly; Way Y Huey; Charles T Taylor
Journal:  Am J Pharm Educ       Date:  2010-08-10       Impact factor: 2.047

Review 6.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

7.  Patient compliance with venous thromboembolism prophylaxis (VTE).

Authors:  John Ross Blackwell; Parag Raval; John-Patrick Quigley; Amit Patel; Donald McBride
Journal:  J Clin Orthop Trauma       Date:  2017-04-14

Review 8.  Venous thromboembolism after spinal cord injury.

Authors:  Robert W Teasell; Jane T Hsieh; Jo-Anne L Aubut; Janice J Eng; Andrei Krassioukov; Linh Tu
Journal:  Arch Phys Med Rehabil       Date:  2009-02       Impact factor: 3.966

9.  A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Kathryn Lanuke; Lloyd A Mack; Walley J Temple
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

10.  Frequency of thromboprophylaxis and incidence of in-hospital venous thromboembolism in a cohort of emergency department patients.

Authors:  Alan E Jones; Zachary Fordham; Vasilios Yiannibas; Charles L Johnson; Jeffrey A Kline
Journal:  J Thromb Thrombolysis       Date:  2007-06-19       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.